Ixekizumab trial

[flagstare]

this is a trial and I may be one of 15 in the UK and 300 world wide.

[Fred]

this is a trial and I may be one of 15 in the UK and 300 world wide.

Good luck I hope it goes well and please do keep this thread updated.

Here is what we have at the moment.

Ixekizumab shows significant improvement for psoriasis patients

Ixekizumab meets it's goals in Phase 3 for psoriatic arthritis.

Lilly's Ixekizumab phase 3

Ixekizumab Normalizes Mutant Psoriasis Genes

Lilly's Ixekizumab Phase II Data

[jiml]

Thanks for starting this thread Tom, it should make interesting reading, I shall look forward to following your progress
Jim

[flagstare]

First appointment today, gallons of blood, chest x ray+ecg. this will be phase 3 of trials for IXEKIZUMAB and will be compared against Ustekinumab ( can't pronounce either without getting tongue twisted ) ( can't pronounce at all ) will involve regular injections and will become self administered, There are / might be some side effects and I will post these once I have read what they are (already have read but have forgotten). next appt is next Tues for bloods to test for TB.

[Grizzly Bear]

Bloody nora. Gallons of blood !!! Lol

Fingers crossed that this trial drug works for you Flag

[flagstare]

Here is some info about IXEKIZUMAB -

Our study is taking place internationally and there will be about 300 other patients all around the world who will be taking part including approximately 15 patients in the UK. It will take about two years to complete the whole study but your participation in the study is expected to last up to one year and three months.

The main reason for you to take part in this study is not to treat you for your condition, we hope that the results of this study will help to answer the following research question:

• Can ixekizumab help patients with moderate-to-severe plaque psoriasis when compared to ustekinumab?

Ustekinumab is recommended by the National Institute for Health and Care
Excellence for the treatment of severe plaque psoriasis which has failed to respond to other
recommended standard treatments. The study compares the recommended treatment,
Ustekinumab, with the investigational medication, Ixekizumab.

. As of 15 September 2014, ixekizumab (LY2439821) has been given to at least 4204 people with psoriasis (Ps), 532 people with rheumatoid arthritis (RA), and approximately 208 people with psoriatic arthritis (PsA).

Ixekizumab is an antibody that has been created to block a protein called interleukin-17 (IL-17) in the body. IL-17 is involved in defence against certain types of infections, but uncontrolled IL-17 production may be involved in certain diseases including RA, Ps, PsA, and axial spondyloarthritis (AS).

Ixekizumab has been given as a subcutaneous (SC) injections under the skin or as an intravenous (IV) infusion into a vein in 12 studies, either as a single dose or as many doses repeated at various time points. In some studies, ixekizumab was given as often as every 2 weeks for at least 12 weeks.



Adverse events that occurred in ≥3% (3 out of 100) of ixekizumab treated patients are listed below, in order from most to least frequent:

Psoriasis Patients
Runny nose and sore throat; cold symptoms
Injection site reaction
Upper respiratory infection
Headache
Joint pain
Sinus irritation
Back pain
Diarrhea
Urinary tract infection
Bronchitis
Injection site redness
High blood pressure


Common side effects (may affect up to 1 in 10 people):
• Diarrhea
• Nausea
• Feeling tired
• Feeling dizzy
• Headache
• Itching (‘pruritus’)
• Back, muscle or joint pain
• Sore throat
• Tooth infections
• Redness and pain where the injection is given.
Uncommon side effects (may affect up to 1 in 100 people):
• Depression
• Blocked or stuffy nose
• Bleeding, bruising, hardness, swelling and itching where the injection is given
• Drooping eyelid and sagging muscles on one side of the face (‘facial palsy’ or ‘Bell’s palsy’), which is usually temporary
• A change in psoriasis with redness and new tiny, yellow or white skin blisters, sometimes accompanied by fever (pustular psoriasis).
• Peeling of the skin (skin exfoliation)
Rare side effects (may affect up to 1 in 1000 people)
• Redness and shedding of skin over a larger area of the body, which may be itchy or painful (exfoliative dermatitis). Similar symptoms sometimes develop as a natural change in the type of psoriasis symptoms (erythrodermic psoriasis).

[jiml]

Thanks for that information Flagstare.
It's a fairly comprehensive document and well worth reading

I hope you get through the trial without any of the adverse side effects, although reading through it looks as if bad side effects are rare ,

Good luck and thanks for keeping us informed

[flagstare]

Have now had my first instalment of IXEKIZUMAB two day's ago and the only thing was yesterday my eye's were a wee bit nippy but no worse than they would be if I was very tired. it involved three injections to my stomach two by the nurse to show me how and then the third by myself "OUCH" Didnae like that at all. while I'm under this treatment I'm not allowed the use of ointments, tablets etc. to enable a clear study of the stuff at work, I am however allowed to use EPADERM Cream which I have been using for a while now and I find to be a very good moisturiser.

[jiml]

it's Great news Tom let's hope you are on the road to clearance of this disease,
So were the the three injections on the same day?  Ouch that sounds nasty the injection you did, but you will get the hang of it, so it won't hurt
Have you taken photos for your benefit so you can chronicle the improvement of your skin,
I look forward to hearing how effective this drug is on you,
Jim

[flagstare]

The three injections were all within 5 mins, photos good idea once I've mastered how to place them on this thread, I am told by the Dr's that I can expect to see a vast improvement within 4 - 5 weeks, they also tell me I am the first on this trial in the UK. Next visit on the 18th Nov.